RABEP2 is a novel GSK3 substrate that represents a single therapeutic target to reduce both hyperglycemia and microvascular disease in diabetes

Project: Research

Project Details

StatusActive
Effective start/end date1/06/2031/05/23

Funding

  • British Heart Foundation BHF: £14,390.00